2022 - Response Prediction in Oncology Clinical Trials

The failure rate of late-stage oncology clinical trials is one of the highest across therapeutic areas, whereas many promising early-stage studies may be prematurely abandoned due to presumably false negative results.
With artificial intelligence (AI) and technology, the relationship between tumour changes and tumour assessment endpoints (ORR, PFS etc.) can be modelled to enhance understanding of the drug mechanism of action in clinical oncology studies.
Join this webinar to meet IAG’s expert team and discuss the latest technological innovations and advanced imaging to support success of oncology clinical trials through quantitative insights.